Details

Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč : doktorska disertacija
ID Koren, Ana (Author), ID Čufer, Tanja (Mentor) More about this mentor... This link opens in a new window, ID Korošec, Peter (Comentor)

.pdfPDF - Presentation file, Download (2,09 MB)
MD5: A9F73324DEF993114265803B781F0EBD
PID: 20.500.12556/rul/d6454d84-3e5f-43c0-a05f-848327dd79a0

Language:Slovenian
Keywords:onkologija, nedrobnocelični karcinom pljuč, matične celice novotvorb, epitelno-mezenhimski prehod, prognoza, cirkulirajoče celice novotvorb, biološki tumorski označevalci
Work type:Dissertation
Typology:2.08 - Doctoral Dissertation
Organization:MF - Faculty of Medicine
Place of publishing:Ljubljana
Publisher:[A. Koren]
Year:2016
Number of pages:XVI, 93 str.
PID:20.500.12556/RUL-84295 This link opens in a new window
UDC:616.24-006(043.3)
COBISS.SI-ID:284476416 This link opens in a new window
Publication date in RUL:29.07.2016
Views:3805
Downloads:1044
Metadata:XML DC-XML DC-RDF
:
KOREN, Ana, 2016, Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč : doktorska disertacija [online]. Doctoral dissertation. Ljubljana : A. Koren. [Accessed 26 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=84295
Copy citation
Share:Bookmark and Share

Secondary language

Language:English
Title:The importance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer : doctoral dissertation
Keywords:oncology, carcinoma non-small-cell lung, neoplastic stem cells, epithelial-mesenchymal transition, prognosis, neoplastic cells circulating, biomarkers tumor

Similar documents

Similar works from RUL:
  1. Systematic review and meta-analysis of observational studies evaluating treatment outcomes in patients with metastatic non-small-cell lung cancer on first-line immune checkpoint inhibitors therapy
  2. Description of adverse event of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer treated at the University Clinic Golnik
  3. Effectivness and safety of immunotherapy in patients with advanced non-small cell lung cancer in second line treatment at the University Clinic Golnik
  4. Evaluation of possible pembrolizumab dosing regimen racionalisation in advanced non-small cell lung cancer
  5. ǂThe ǂpotential of immunotherapies in the treatment of lung cancer
Similar works from other Slovenian collections:
  1. ǂThe ǂrole of immune checkpoint inhibitors in the treatment of cancer of unknown origin
  2. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA)
  3. Febrile neutropenia and grade 3/4 neutropenia in daily practice of adjuvant chemotherapy for non-small-cell lung cancer
  4. Advances in the therapy with immune-check point inhibitors (ICI) in non-small cell lung cancer (NSCLC) in 2022
  5. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Back